Comparative Pharmacology
Head-to-head clinical analysis: KERLEDEX versus OTICAIR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: KERLEDEX versus OTICAIR.
KERLEDEX vs OTICAIR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Kerledex is a selective serotonin reuptake inhibitor (SSRI) that potentiates serotonergic activity in the CNS by inhibiting the reuptake of serotonin at the presynaptic neuronal membrane.
Ciprofloxacin inhibits bacterial DNA gyrase and topoisomerase IV, disrupting DNA replication; fluocinolone acetonide is a corticosteroid that induces phospholipase A2 inhibitory proteins, reducing prostaglandin and leukotriene synthesis, thereby suppressing inflammation.
Intravenous: 500 mg every 6 hours; Oral: 250 mg every 8 hours.
1-2 sprays into each affected ear twice daily for 7 days. Topical route.
None Documented
None Documented
Terminal half-life 12 hours (range 10–14) in normal renal function; extended to 30–50 hours in severe renal impairment (CrCl <30 mL/min); 6–8 hours in hepatic cirrhosis.
4.2 hours; prolonged in renal impairment (up to 12 hours in creatinine clearance <30 mL/min)
Renal: 70% unchanged; fecal/biliary: 20% as metabolites; 10% as minor metabolites. Total renal clearance 180 mL/min, active tubular secretion accounts for 60% of renal elimination.
Renal: 85% unchanged; biliary/fecal: 10%
Category C
Category C
Corticosteroid/Antibiotic Combination
Otic Antibiotic/Corticosteroid